Q2 Earnings Forecast for DGX Issued By Leerink Partnrs

Quest Diagnostics Incorporated (NYSE:DGX) – Stock analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for shares of Quest Diagnostics in a research note issued on Tuesday, April 22nd. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings per share of $2.56 for the quarter, down from their prior estimate of $2.58. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Quest Diagnostics’ current full-year earnings is $9.70 per share. Leerink Partnrs also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.41 EPS and FY2025 earnings at $9.72 EPS.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, February 6th. Citigroup lowered Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.00 target price on the stock. in a research report on Tuesday, March 4th. Leerink Partners raised Quest Diagnostics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $169.00 to $174.00 in a research note on Monday, January 6th. Barclays increased their target price on Quest Diagnostics from $175.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, Mizuho lifted their target price on Quest Diagnostics from $178.00 to $189.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics has an average rating of “Moderate Buy” and an average price target of $183.73.

Quest Diagnostics Stock Up 1.4 %

Shares of NYSE:DGX opened at $175.92 on Thursday. The company has a market capitalization of $19.63 billion, a price-to-earnings ratio of 22.88, a PEG ratio of 2.16 and a beta of 0.78. Quest Diagnostics has a 12-month low of $134.05 and a 12-month high of $178.87. The business has a 50-day moving average price of $168.88 and a 200 day moving average price of $160.81. The company has a current ratio of 1.10, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.06. The company had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%.

Institutional Trading of Quest Diagnostics

Hedge funds have recently made changes to their positions in the company. BankPlus Wealth Management LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at about $355,000. Van ECK Associates Corp raised its stake in shares of Quest Diagnostics by 980.3% during the 4th quarter. Van ECK Associates Corp now owns 24,198 shares of the medical research company’s stock worth $3,650,000 after buying an additional 21,958 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Quest Diagnostics in the 4th quarter valued at approximately $54,000. Clean Yield Group boosted its stake in shares of Quest Diagnostics by 17.7% in the fourth quarter. Clean Yield Group now owns 26,428 shares of the medical research company’s stock valued at $3,987,000 after buying an additional 3,983 shares in the last quarter. Finally, SVB Wealth LLC acquired a new position in Quest Diagnostics during the fourth quarter worth $10,345,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Buying and Selling

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 535 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $169.71, for a total value of $90,794.85. Following the transaction, the executive vice president now directly owns 71,356 shares in the company, valued at approximately $12,109,826.76. This trade represents a 0.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $164.30, for a total value of $66,212.90. Following the completion of the transaction, the senior vice president now directly owns 4,624 shares in the company, valued at approximately $759,723.20. The trade was a 8.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,903 shares of company stock worth $9,460,221 in the last 90 days. Company insiders own 8.16% of the company’s stock.

Quest Diagnostics Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 21st. Investors of record on Monday, April 7th were given a $0.80 dividend. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Monday, April 7th. This represents a $3.20 annualized dividend and a yield of 1.82%. Quest Diagnostics’s dividend payout ratio is 40.46%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.